With respect, the many various and conflicting opinions...

With respect, the many various and conflicting opinions expressed on the matter, suggesting that anything that bucks the usual confirmation bias and has substance is itself subject to bias.

Even the idea of countering confirmation bias can be biased, as it implies that an opposing view is automatically more critical or objective, which may not always be the case, which of course this post deserves that same scrutiny.

While the current disappointment regarding Anteris’ NASDAQ entry is understandable, the situation is likely more complex than a simple failure to realise value. Several key factors could explain the stock’s performance.

The broader economic climate, including inflation and shifting investor sentiment, has affected many companies, particularly in biotech. Anteris’ market capitalisation likely reflects these external pressures, not necessarily a failure on the company’s part.

Anteris’ relatively conservative spending on its IP compared to competitors could indicate fiscal responsibility. Instead of overspending, the company is taking a measured, sustainable approach, which might protect shareholder value in the long run.

Short-term fluctuations in stock price don’t always reflect a company’s intrinsic value. Current market forces may obscure Anteris’ long-term potential, which could still offer growth opportunities for patient investors.

Though the NASDAQ entry may not have generated significant buzz, it remains a major achievement. Being on this prestigious exchange increases Anteris’ visibility and opens doors for future growth.

While Anteris’ IP hasn’t yet reached the same valuation as its competitors, innovation in biotech often takes time. The company’s IP may still prove to be a “company maker” with time and developmenGt.

Despite short-term frustrations, factors like market conditions, cautious funding, and long-term potential suggest that Anteris’ value is still unfolding. The NASDAQ listing could be the start of future growth rather than a missed opportunity.